News|Articles|August 3, 2026

5 Endocrinology Headlines You Missed in July 2026

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

July 2026 was relatively quiet for endocrinology. The US Food and Drug Administration (FDA) had no significant approvals, instead accepting 2 exciting New Drug Applications (NDAs) for the treatment of hypocalcemia and acromegaly, respectively. Additionally, key trials for type 1 diabetes (T1D), type 2 diabetes (T2D), and weight maintenance following GLP-1 RA discontinuation had topline results read out over the course of the month, moving major candidates like encaleret and tegoprubart further down the treatment pipeline towards an FDA decision.

Related to this article

October 28th, 2026

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Retatrutide lowered A1C 2.2% vs 1.8% and cut weight 19.5%-20.9% vs 9.4% with semaglutide 2 mg at 80 weeks in adults with type 2 diabetes.

October 23rd, 2026

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

October 27th, 2026

Diabetes Dialogue: Building A Consensus Definition for Fully Closed-Loop Systems

Brynn Marks, MD, MSHPEd, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss a new framework defining fully closed loop insulin delivery.

October 30th, 2026

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.

October 30th, 2026

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice

October 30th, 2026

Mitapivat PDUFA Date for Sickle Cell Disease Extended to February 2027

The FDA has pushed its decision on mitapivat for sickle cell disease to February 1, 2027, while it reviews updated safety data to decide whether a REMS is needed.

October 27th, 2026

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Vanda’s oral NK-1 receptor antagonist cut any vomiting by 27% vs placebo after a single 1 mg semaglutide dose, and the company plans an sNDA submission.

October 23rd, 2026

FDA Approves Subcutaneous Risankizumab Induction for Crohn’s Disease

Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.